DOCSLIB.ORG

Alpha-2 Adrenergic Agonists to Prevent Perioperative Cardiovascular Complications: a Meta-Analysis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Alpha-2 Adrenergic Agonists to Prevent Perioperative Cardiovascular Complications: a Meta-Analysis SPECIAL ARTICLE Alpha-2 Adrenergic Agonists to Prevent Perioperative Cardiovascular Complications: A Meta-analysis Duminda N. Wijeysundera, MD, Jennifer S. Naik, MD, W. Scott Beattie, MD, PhD ␣ ϭ ϭ PURPOSE: To investigate the effects of 2-adrenergic agonists 0.99; P 0.05) and ischemia (RR 0.76; 95% CI: 0.63 to 0.91; on perioperative mortality and cardiovascular complications in P ϭ 0.003) significantly. They also reduced mortality (RR ϭ adults undergoing surgery. 0.47; 95% CI: 0.25 to 0.90; P ϭ 0.02) and myocardial infarction METHODS: MEDLINE (1966 to May 2002), EMBASE (1980 (RR ϭ 0.66; 95% CI: 0.46 to 0.94; P ϭ 0.02) during vascular to May 2002), the Cochrane Clinical Trials Register, the Science ␣ surgery. During cardiac surgery, 2-adrenergic agonists re- Citation Index, and bibliographies of included articles were duced ischemia (RR ϭ 0.71; 95% CI: 0.54 to 0.92; P ϭ 0.01) and searched without language restriction. Randomized trials com- were associated with trends toward lower mortality (RR ϭ 0.49; paring preoperative, intraoperative, or postoperative (first 48 95% CI: 0.12 to 1.98; P ϭ 0.3) and a reduced risk of myocardial hours) administration of clonidine, dexmedetomidine, or infarction (RR ϭ 0.83; 95% CI: 0.35 to 1.96; P ϭ 0.7). mivazerol with controls were included. Studies had to report CONCLUSION: Alpha-2 adrenergic agonists reduce mortality any of the following outcomes: mortality, myocardial infarc- and myocardial infarction following vascular surgery. During tion, ischemia, or supraventricular tachyarrhythmia. Treat- cardiac surgery, they reduce ischemia and may also have effects ment effects were calculated using the fixed-effects model. Het- on mortality and myocardial infarction. Large randomized erogeneity was assessed using the Q test. RESULTS: Twenty-three trials comprising 3395 patients were trials are needed to evaluate these agents during cardiac and ␣ vascular surgery. Am J Med. 2003;114:742–752. ©2003 by included. Overall, 2-adrenergic agonists reduced mortality (relative risk [RR] ϭ 0.64; 95% confidence interval [CI]: 0.42 to Excerpta Medica Inc. ␣ ardiovascular complications following cardiac diovascular complications. Unlike 1-antagonists (e.g., and noncardiac surgery increase mortality, mor- prazosin), which act on peripheral adrenergic receptors bidity, and health care costs (1–4). Approxi- ␣ C to inhibit vasoconstriction directly, 2-agonists act on mately 4.5% of patients undergoing cardiac surgery will central and presynaptic receptors to inhibit central sym- have a perioperative myocardial infarction (1), whereas pathetic outflow (7) and reduce peripheral norepineph- about 30% of patients undergoing noncardiac surgery rine release (8). Alpha-2 agonists dilate poststenotic have, or are at risk of, coronary artery disease (3). The coronary vessels (9) and attenuate the severity of periop- direct health care costs of these complications have been erative hemodynamic abnormalities (10,11), and conse- estimated at U.S. $20 billion (3). quently were conferred a grade IIb recommendation in The surgical stress response is important in the patho- the 2002 American College of Cardiology/American ␣ genesis of cardiovascular complications (5,6). The 2-ad- Heart Association Guideline Update on Perioperative renergic agonists currently used in clinical practice— Cardiovascular Evaluation for Noncardiac Surgery (12). clonidine, dexmedetomidine, and mivazerol—attenuate This recommendation, however, was based on one study the stress response and therefore potentially reduce car- (13). A prior meta-analysis concluded that clonidine re- From the Department of Anesthesia (DNW, JSN, WSB), University of duced perioperative ischemia significantly (14). How- Toronto, and Toronto General Hospital (WSB), University Health Net- work, Toronto, Ontario, Canada. ever, the review was underpowered (664 patients in seven Dr. Wijeysundera is the recipient of the Dr. Allan K. Laws Clinician studies), searched only English-language literature, and Scientist Fellowship from the University of Toronto, Ontario, Canada. reported effects only on ischemia, a surrogate outcome. It Requests for reprints should be addressed to W. Scott Beattie, MD, PhD, Department of Anesthesia, University of Toronto, EN 3-453, To- did not include trials of mivazerol or dexmedetomidine, ronto General Hospital, 200 Elizabeth Street, Toronto, Ontario, M5G which have enrolled up to 1900 patients (13). A system- 2C4, Canada, or [email protected]. ␣ Manuscript submitted September 11, 2002, and accepted in revised atic review of perioperative 2-agonists is therefore justi- form February 11, 2003. fied. 742 © 2003 by Excerpta Medica Inc. 0002-9343/03/$–see front matter All rights reserved. doi:10.1016/S0002-9343(03)00165-7 Table 1. Characteristics of Included Studies First Author Number of Coronary Concealed Jadad (Reference) Patients Artery Disease Procedure Alpha-2 Agonist Control Blinding Allocation Score* Cardiac surgery Abi-Jaoude (21) 24 ϩ Coronary bypass grafting Oral clonidine 5 ␮g/kg 120 minutes before surgery Placebo ϩ Unclear 3 Boldt (22) 44 ϩ Coronary bypass grafting Intravenous clonidine 0.05 ␮g/kg/min from induction Placebo ϩ Unclear 3 Alpha-2 adrenergic agonists to prevent perioperative cardiovascular complications/Wijeysundera et al to cardiopulmonary bypass Dorman (23) 43 ϩ Coronary bypass grafting Oral clonidine 5 ␮g/kg 90 minutes before surgery, and Placebo ϩ Unclear 3 5 ␮g/kg before cardiopulmonary bypass Ghignone (24) 24 ϩ Coronary bypass grafting Oral clonidine 5 ␮g/kg 90 minutes before surgery Control Ϫ Unclear 1 Helbo-Hansen 40 ϩ Coronary bypass grafting Intravenous clonidine 7 ␮g/kg in three divided Placebo Ϫ Unclear 1 (26) intraoperative bolus doses Jalonen (27) 80 ϩ Coronary bypass grafting Intravenous dexmedetomidine 50 ng/kg/min before Placebo ϩ Unclear 3 surgery for 30 minutes, 7 ng/kg/min intraoperatively Loick (29) 45 ϩ Coronary bypass grafting Intravenous clonidine 4 ␮g/kg before surgery, 1 ␮g/kg/ Control Ϫ Unclear 2 min intraoperatively, and 0.2–0.5 ␮g/kg/min for 48 hours postoperatively Myles (31) 150 ϩ Coronary bypass grafting Oral clonidine 5 ␮g/kg 90 minutes before surgery, and Placebo ϩ Unclear 4 ␮ June 15, 2003 T 5 g/kg before coronary bypass grafting Quintin (33) 26 ϩ Coronary bypass grafting Oral clonidine 2.5 ␮g/kg 90 minutes before surgery Placebo ϩ Unclear 3 Venn (38) 105 ϩ Mixed (83% cardiac) Intravenous dexmedetomidine 1 ␮g/kg within 1 hour Placebo ϩ Unclear 4 after surgery, and 0.2–0.7 ␮g/kg/h for 6–24 hours Noncardiac surgery ϩ ϩϩ HE Ellis (8) 61 Noncardiac surgery Transdermal clonidine (0.2 mg/d) for 72 hours from Placebo 4 A (82% vascular) night before surgery, and 0.3 mg orally 60–90 minutes MERICAN before surgery Ghignone (25) 30 ϩ Nonvascular surgery Oral clonidine 5 ␮g/kg 90 minutes before surgery Control Ϫ Unclear 2 ϩ ␮ ϩ J Lipszye (28) 40 Carotid artery surgery Oral clonidine 4 g/kg 90 minutes before surgery Placebo Unclear 2 OURNAL OF Mangano (10) 317 ϩ Vascular surgery Two intravenous mivazerol regimens: low (2 ␮g/kg Placebo ϩ Unclear 4 bolus and 0.75 ␮g/kg/h), high (4 ␮g/kg bolus and 1.5 ␮g/kg/h). Bolus given 20 minutes before surgery; M EDICINE infusion until 72 hours after surgery Matot (30) 36 Unclear Airway surgery Oral clonidine 300 ␮g 90 minutes before surgery Placebo ϩ Unclear 3 Oliver (13) 1897† ϩ Noncardiac surgery Intravenous mivazerol 4 ␮g/kg 20 minutes before Placebo ϩϩ4 ௡ surgery, and 1.5 ␮g/kg/h for 72 hours Volume 114 Pluskwa (32) 30 ϩ Carotid artery surgery Oral clonidine 300 ␮g 90 minutes before surgery Placebo ϩϩ5 Quintin (34) 24 ϩ Aortic surgery Oral clonidine 6 ␮g/kg 120 minutes before surgery, Placebo ϩ Unclear 4 and 3 ␮g/kg intravenously after surgery Stuhmeier (35) 297 ϩ Vascular surgery Oral clonidine 2 ␮g/kg 90 minutes before surgery Placebo ϩ Unclear 5 743 Alpha-2 adrenergic agonists to prevent perioperative cardiovascular complications/Wijeysundera et al METHODS Jadad Score* This review adhered to the recommendations of the Quality of Reporting of Meta-analyses (QUOROM) group (15). Unclear 4 Unclear 2 Unclear 4 Unclear 4 Allocation Concealed Inclusion and Exclusion Criteria Eligible studies were published, randomized controlled ϩ Ϫ ϩ ϩ trials that enrolled adults (age Ͼ18 years) who were un- dergoing surgery under general or neuroaxial (spinal or epidural) anesthesia. Trials that recruited patients under- going local anesthesia or peripheral nerve blockade alone were excluded. We also excluded trials that recruited pa- 3 mg/kg/ – propofol 1 mg/kg and 1 h infusion tients who were pregnant, organ transplant recipients, or Placebo Intravenous Placebo Placebo suffering from substance withdrawal. The interventions assessed were preoperative (within g/ 24 hours), intraoperative, or postoperative (within 48 ␮ hours) administration of clonidine, dexmedetomidine, or mivazerol via intravenous, intramuscular, oral, or 24 hours – transdermal routes. Trials had to report any of the follow- g intraoperative ing outcomes: death, myocardial infarction, myocardial g/kg within 1 hour ␮ ␮ g/kg within 6 hours ischemia, or supraventricular tachyarrhythmia. We did ␮ g/kg), high (8.03 ␮ not employ a uniform definition of myocardial infarc- g/kg/h for 6 ␮ tion given the lack of a standardized criterion in the liter- g/kg/h for 72 hours 0.5 ␮ – ature. Ischemia was defined as ST-segment deviation on g/min until 48 hours after surgery ␮ an electrocardiogram or new wall motion abnormalities on a transesophageal echocardiogram. Supraventricular tachyarrhythmias included atrial fibrillation, atrial flut- ter, and supraventricular tachycardia. g/kg), medium (5.31 ␮ Search Strategy (2.64 after surgery, and 0.2 infusion, and 0.15 kg)] as 48-hour infusion from start of surgery after surgery, and 0.4 We identified eligible trials using MEDLINE (1966 to May 2002), EMBASE (1980 to May 2002), and the Cochrane Clinical Trials Register (The Cochrane Library, Issue 2, 2002) (16).
Load more

Recommended publications
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Approaches to the Prevention of Perioperative Myocardial Ischemia
    253 m CLINICAL CONCEPTS AND COMMENTARY Richard B. Weiskopf, M.D., Editor Anesthesiology 2000; 92:253–9 © 2000 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Approaches to the Prevention of Perioperative Myocardial Ischemia Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/92/1/253/398628/0000542-200001000-00038.pdf by guest on 25 September 2021 David C. Warltier, M.D., Ph.D.,* Paul S. Pagel, M.D., Ph.D.,† Judy R. Kersten, M.D.† PREVENTION of perioperative myocardial ischemia is on the horizon promise to reduce the risk of myocardial essential to avoid the mechanical, metabolic, and elec- ischemia or infarction. Although some of these new trophysiologic changes associated with acute imbal- drugs act by altering the myocardial oxygen supply/ ances in the relationship between myocardial oxygen demand relationship, others directly protect myocar- supply and demand. Myocardial ischemia of sufficient dium from ischemic injury. This brief review outlines severity or prolonged duration may result in reversible established methods used for the prevention of myocar- (e.g., myocardial stunning) or irreversible (e.g., infarc- dial ischemia and also discusses potential future thera- tion) damage, malignant ventricular arrhythmias, or car- peutic strategies that may attenuate the reversible and diogenic shock. These potentially disastrous conse- irreversible sequelae of ischemia. At present, the major- quences are associated with high morbidity and ity of data has been obtained in patients with severe mortality in patients with coronary artery disease. Elec- coronary artery disease undergoing coronary artery by- pass graft surgery. The applicability of results obtained in tive surgical procedures may be delayed until unstable this patient population must be extrapolated with care coronary artery disease is treated by angioplasty or sur- to patients with less severe coronary disease or those gical revascularization.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Wirkung Von Sekretin Auf Neurotransmitter Im Hippokampus Der Ratte
    Aus der Abteilung für Psychiatrie und Psychotherapie im Kindes- und Jugendalter, Universitätsklinik für Psychiatrie und Psychosomatik der Albert-Ludwigs-Universität Freiburg Direktor: Prof. Dr. E. Schulz WIRKUNG VON SEKRETIN AUF NEUROTRANSMITTER IM HIPPOKAMPUS DER RATTE Inaugural-Dissertation zur Erlangung des Medizinischen Doktorgrades der Medizinischen Fakultät der Albert-Ludwigs-Universität Freiburg im Breisgau Vorgelegt 2003 VON ANDRÉ KUNTZ Geboren in Thionville (F) Dekan: Prof. Dr. med. Christoph Peters Erster Gutachter: PD Dr. rer. nat. H.-W. Clement Zweiter Gutachter: Prof. Dr. Dr. med. D. van Calker Jahr der Promotion: 2006 MEINEN ELTERN GEWIDMET I INHALTSVERZEICHNIS ___________________________________________________________________________ INHALTSVERZEICHNIS INHALTSVERZEICHNIS I ABKÜRZUNGSVERZEICHNIS IV ABBILDUNGSVERZEICHNIS VI TABELLENVERZEICHNIS VII GLEICHUNGSVERZEICHNIS VII 1 EINLEITUNG 1 1.1 SEKRETIN 4 1.1.1 GESCHICHTE 4 1.1.2 STRUKTUR 5 1.1.3 SYNTHESE 6 1.1.4 FUNKTIONSWEISE VON SEKRETIN 6 1.1.5 KLINISCHE ANWENDUNG VON SEKRETIN 7 1.1.6 SEKRETINREZEPTOREN 8 1.1.7 SEKRETIN BEI VERSCHIEDENEN SPEZIES 9 1.1.8 ZNS 10 1.1.9 FUNKTION IM GASTROINTESTINALTRAKT 12 1.1.10 SEKRETIN/ VIP/ PACAP-SUPERFAMILIE 13 1.1.11 HYPOKRETINE/OREXINE 14 1.1.12 AUTISMUS 15 1.1.12.1 Geschichte des Autismus 15 1.1.12.2 Häufigkeit 16 1.1.12.3 Krankheitsbild 16 1.1.12.4 Ursachen und Komorbidität 17 1.1.12.5 Therapie 17 1.2 NEUROTRANSMITTER UND AUTISMUS 20 1.2.1 GLUTAMAT 21 1.2.2 GABA 24 1.2.3 KATECHOLAMINE 25 1.2.3.1 Noradrenalin und Adrenalin 26 1.2.3.2
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0113826A1 Fallon Et Al
    US 201401 13826A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0113826A1 Fallon et al. (43) Pub. Date: Apr. 24, 2014 (54) POLYSACCHARIDE ESTERMICROSPHERES A24D3/14 (2006.01) AND METHODS AND ARTICLES RELATING A618/02 (2006.01) THERETO (52) U.S. Cl. (71) Applicant: Celanese Acetate LLC, Irving, TX (US) CPC ............. A2.3L I/22016 (2013.01); A61K 8/025 (2013.01); A0IN 25/34 (2013.01); A24D 3/14 (72) Inventors: Denis G. Fallon, Blacksburg, VA (US); (2013.01) Thomas S. Garrett, Narrows, VA (US); USPC 504/358; 424/401; 424/405; 424/64; 424/69; Lawton E. Kizer, Blacksburg, VA (US); 424/63; 424/70.7; 13 1/332: 426/650: 426/648 Karen L. Zazzara, Blacksburg, VA (US); Michael T. Combs, Shady Spring, WV (US); Richard K. Johnson, Blacksburg, VA (US); Gary Dehart, (57) ABSTRACT Peterstown, WV (US) (73) Assignee: Celanese Acetate LLC, Irving, TX (US) A method for producing a polysaccharide ester microsphere may include forming a polysaccharide ester product from a (21) Appl. No.: 14/060,782 polysaccharide synthesis, wherein the polysaccharide ester (22) Filed: Oct. 23, 2013 product comprises a polysaccharide ester and a solvent, dilut e a? a 9 ing the polysaccharide ester product, thereby yielding a Related U.S. Application Data polysaccharide ester dope; and forming a plurality of polysaccharide ester microspheres from the polysaccharide (60) Provisional application No. 61/717,726, filed on Oct. ester dope. Suitable polysaccharides may include, but are not 24, 2012. limited to, starch, cellulose, hemicellulose, algenates, chito Publication Classification san, and any combination thereof.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, following to be employed in commercial fishing or the commercial UST, MXT, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0184806 A1 Barlow Et Al
    US 20100184806A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0184806 A1 Barlow et al. (43) Pub. Date: Jul. 22, 2010 (54) MODULATION OF NEUROGENESIS BY PPAR (60) Provisional application No. 60/826,206, filed on Sep. AGENTS 19, 2006. (75) Inventors: Carrolee Barlow, Del Mar, CA (US); Todd Carter, San Diego, CA Publication Classification (US); Andrew Morse, San Diego, (51) Int. Cl. CA (US); Kai Treuner, San Diego, A6II 3/4433 (2006.01) CA (US); Kym Lorrain, San A6II 3/4439 (2006.01) Diego, CA (US) A6IP 25/00 (2006.01) A6IP 25/28 (2006.01) Correspondence Address: A6IP 25/18 (2006.01) SUGHRUE MION, PLLC A6IP 25/22 (2006.01) 2100 PENNSYLVANIA AVENUE, N.W., SUITE 8OO (52) U.S. Cl. ......................................... 514/337; 514/342 WASHINGTON, DC 20037 (US) (57) ABSTRACT (73) Assignee: BrainCells, Inc., San Diego, CA (US) The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system (21) Appl. No.: 12/690,915 including by stimulating or increasing neurogenesis, neuro proliferation, and/or neurodifferentiation. The disclosure (22) Filed: Jan. 20, 2010 includes compositions and methods based on use of a peroxi some proliferator-activated receptor (PPAR) agent, option Related U.S. Application Data ally in combination with one or more neurogenic agents, to (63) Continuation-in-part of application No. 1 1/857,221, stimulate or increase a neurogenic response and/or to treat a filed on Sep. 18, 2007. nervous system disease or disorder. Patent Application Publication Jul. 22, 2010 Sheet 1 of 9 US 2010/O184806 A1 Figure 1: Human Neurogenesis Assay Ciprofibrate Neuronal Differentiation (TUJ1) 100 8090 Ciprofibrates 10-8.5 10-8.0 10-7.5 10-7.0 10-6.5 10-6.0 10-5.5 10-5.0 10-4.5 Conc(M) Patent Application Publication Jul.
    [Show full text]
  • WO 2009/065116 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date (10) International Publication Number 22 May 2009 (22.05.2009) PCT WO 2009/065116 Al (51) International Patent Classification: (74) Agent: MILLER, Raymond A.; Pepper Hamilton LLP, AOlN 65/00 (2009.01) 500 Grant Street, 50th Floor, One Mellon Center, Pitts burgh, Pennsylvania 15219 (US). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/US2008/083774 kind of national protection available): AE, AG, AL, AM, AO, AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, (22) International Filing Date: CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, 17 November 2008 (17.1 1.2008) EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (25) Filing Language: English LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, (26) Publication Language: English RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY,TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: ZW 60/988,564 16 November 2007 (16.1 1.2007) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): ASPECT GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, PHARMACEUTICALS LLC [US/US]; 4351 E.
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]
  • (12) United States Patent (Lo) Patent No.: US 8,480,637 B2
    111111111111111111111111111111111111111111111111111111111111111111111111 (12) United States Patent (lo) Patent No.: US 8,480,637 B2 Ferrari et al. (45) Date of Patent : Jul. 9, 2013 (54) NANOCHANNELED DEVICE AND RELATED USPC .................. 604/264; 907/700, 902, 904, 906 METHODS See application file for complete search history. (75) Inventors: Mauro Ferrari, Houston, TX (US); (56) References Cited Xuewu Liu, Sugar Land, TX (US); Alessandro Grattoni, Houston, TX U.S. PATENT DOCUMENTS (US); Daniel Fine, Austin, TX (US); 5,651,900 A 7/1997 Keller et al . .................... 216/56 Randy Goodall, Austin, TX (US); 5,728,396 A 3/1998 Peery et al . ................... 424/422 Sharath Hosali, Austin, TX (US); Ryan 5,770,076 A 6/1998 Chu et al ....................... 210/490 5,798,042 A 8/1998 Chu et al ....................... 210/490 Medema, Pflugerville, TX (US); Lee 5,893,974 A 4/1999 Keller et al . .................. 510/483 Hudson, Elgin, TX (US) 5,938,923 A 8/1999 Tu et al . ........................ 210/490 5,948,255 A * 9/1999 Keller et al . ............. 210/321.84 (73) Assignees: The Board of Regents of the University 5,985,164 A 11/1999 Chu et al ......................... 516/41 of Texas System, Austin, TX (US); The 5,985,328 A 11/1999 Chu et al ....................... 424/489 Ohio State University Research (Continued) Foundation, Columbus, OH (US) FOREIGN PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this WO WO 2004/036623 4/2004 WO WO 2006/113860 10/2006 patent is extended or adjusted under 35 WO WO 2009/149362 12/2009 U.S.C. 154(b) by 612 days.
    [Show full text]
  • Rana Dadashova
    University of Alberta Is Atomoxetine effective in treating nicotine withdrawal? A double-blind, placebo-controlled, fixed-dose study by Rana Dadashova A thesis submitted to the Faculty of Graduate Studies and Research in partial fulfillment of the requirements for the degree of Master of Science Department of Psychiatry ©Rana Dadashova Fall 2011 Edmonton, Alberta Permission is hereby granted to the University of Alberta Libraries to reproduce single copies of this thesis and to lend or sell such copies for private, scholarly or scientific research purposes only. Where the thesis is converted to, or otherwise made available in digital form, the University of Alberta will advise potential users of the thesis of these terms. The author reserves all other publication and other rights in association with the copyright in the thesis and, except as herein before provided, neither the thesis nor any substantial portion thereof may be printed or otherwise reproduced in any material form whatsoever without the author's prior written permission. Dedication This work is dedicated to my lovely husband Mehti Dadashov and my dear children Seymur and Kamilla, whose love, inspiration and great support made this project successful. I also dedicate these theses to my dear parents Vera Stadnik and Valeriy Stadnik, whose deepest love and couching has been navigating me throughout my life. Abstract Drugs that affect noradrenaline neurotransmission are used as therapy for smoking cessation. A recent study in individuals with attention-deficit and hyperactivity disorder (ADHD) suggested that atomoxetine, a noradrenaline reuptake inhibitor, may reduce cravings in individuals with ADHD who also smoked. The present double-blind, placebo-controlled, fixed-dose study investigated the effect of atomoxetine on nicotine withdrawal in otherwise healthy smokers, who has no psychiatric condition, and wish to stop smoking.
    [Show full text]